Takeda acquires selected international rights to AMAG's anaemia product Feraheme
This article was originally published in Scrip
Executive Summary
AMAG Pharmaceuticals has licensed its anaemia product Feraheme (ferumoxytol) to Takeda for several major markets worldwide, in an alliance worth up to $280 million in upfront, development and commercial milestone payments to the US firm.